Amadix
PancreaDix - Non-Invasive Signature in Blood Test Cutting Edge Liquid Biopsy Technology
FromAmadix
PancreaDix is an innovative, non-invasive signature in blood for: Confirming a Pancreatic cancer diagnosis. Detecting pre-malignant lesions that will evolve to cancer. Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors.
Most popular related searches
pancreas cancer
liquid biopsy system
cancer diagnosis
pancreatic cyst
pancreas
blood sampling
biopsy
liquid biopsy
biopsy system
blood testing
PancreaDix® identifies and measures biomarkers which are differentially expressed in blood samples of individuals with Pancreatic Cancer (PaC)
- Genetic biomarkers
- Non-invasive test in plasma
- Easy, low cost and a common technique for hospitals and laboratories
- Confirming Pancreatic cancer diagnosis, identifying benign vs. malign pancreatic cysts to avoid unnecessary surgeries and differential diagnosis between Pancreatic cancer and other pathologies.
PancreaDix® will typically be prescribed by the Gastroenterologist or the General Practitioner to patients with:
- Incidental findings in the pancreas
- Symptoms compatible with pancreatic cancer.
- Case of chronic pancreatitis or neuroendocrine tumors to confirm that it is not cancer.
- Case of cysts to diagnose their potential malignancy to proceed with surgery or not.
- Inconclusive biopsies or images.
- High-risk for Pancreatic Cancer, recommended for screening (this group of patients should be included in future studies).
PancreaDix® will improve the early detection of premalignant and malignant lesions of pancreatic cancer and it enables physicians to better manage patients with pancreatic cancer and other pancreatic pathologies.
There are no national or international screening programs for pancreatic cancer. PancreaDix® would also serve as a screening tool for an eligible high-risk population due to hereditary risk or long-standing diabetes.